Last reviewed · How we verify
Methylene blue infusion
A monoamine oxidase inhibitor
A monoamine oxidase inhibitor Used for Treatment of methemoglobinemia, Diagnostic aid for certain conditions.
At a glance
| Generic name | Methylene blue infusion |
|---|---|
| Also known as | Methylene blue, Phenothiazines |
| Sponsor | Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva |
| Drug class | Monoamine oxidase inhibitor |
| Target | Monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Methylene blue acts as a potent inhibitor of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), which are enzymes responsible for the breakdown of monoamines such as dopamine, serotonin, and norepinephrine.
Approved indications
- Treatment of methemoglobinemia
- Diagnostic aid for certain conditions
Common side effects
- Hypotension
- Tachycardia
- Headache
Key clinical trials
- Early Methylene Blue in the Microhemodynamics of Septic Patients (PHASE2, PHASE3)
- Adjunctive Methylene Blue in Septic Shock (PHASE3)
- Clinical Trial to Evaluate the Efficacy and Safety of SUBMO® as a Submucosal Injection Agent in Endoscopic Resection of Superficial Gastrointestinal Lesions. (NA)
- Methylene Blue for the Treatment of Septic Shock (PHASE3)
- A Multidisciplinary Perioperative Pain Management (NA)
- A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses (PHASE2)
- Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study (PHASE1)
- Endoscopic Gastroenterostomy Versus Surgical Gastrojejunostomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |